Food and Drug
Administration
Oncologic
Drugs Advisory Committee
Briefing Information
September 7, 2006
Genta Incorporated
Disclaimer
The statements contained in this document(s) are those of
the product’s sponsor, not FDA, and FDA does not necessarily
agree with the sponsor’s statements. FDA has not made
a final determination about the safety or effectiveness of
the product described in this document.
Abraxis Bioscience, Inc Briefing Material for Abraxane (pdf)
FDA
Disclaimer
Portions of this document have been determined to be exempt
from disclosure under the Freedom of Information Act (the
FOIA) (5 U.S.C. § 552).
These redacted portions will appear as white space on the
screen or on the printed page.
FDA Briefing Material for NDA 21-660 (pdf)